An ANGPTL4 inhibitory antibody safely improves lipid profiles in non-human primatesResearch in context

Summary: Background: Angiopoietin-like protein 4 (ANGPTL4) inhibition is a promising approach to manage atherogenic dyslipidaemia and residual atherosclerotic cardiovascular disease (ASCVD) risk. Human ANGPTL4 loss-of-function (LoF) is associated with reduced plasma triglyceride (TG), remnant chole...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Beryl B. Cummings, Page R. Bouchard, Mark N. Milton, Peter F. Moesta, Vyas Ramanan, John W. Trauger, Eleftheria Maratos-Flier, Andrei Voznesensky, Igor Splawski, Amitabh V. Nimonkar, Keith DiPetrillo, Daniel LaSala, Meihui Pan, Meghan M. Flaherty, Francois Huet, Sukhdeep K. Sahambi, Jijun Dong, Deborah Knee, Regis Cebe, Thomas Huber, Joshua Lehrer-Graiwer, Rebecca A. Juliano, Ethan J. Weiss
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Elsevier 2025-07-01
Reeks:	EBioMedicine
Onderwerpen:	MAR001 ANGPTL4 Triglyceride Remnant cholesterol Non-human primates Safety
Online toegang:	http://www.sciencedirect.com/science/article/pii/S2352396425001926
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!